CONTROL OF NEURODEGENERATIVE DISEASES WITH BENZOTHIAZOLE-BENZAMIDE DERIVATIVES

CSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. 

Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought.